drugset / Trial / NCT01892189
Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults
RandomizedCrossoverQuadruple-blindBasic science
Summary
The purpose of this study is to determine whether ketamine-induced brain activity changes are modulated by TAK-063 administration using neuroimaging battery tests.
Timeline
- Start
- 2013-08
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BALIPODECT | Small molecule | 3 mg | Oral |
| Subject | BALIPODECT | Small molecule | 10 mg | Oral |
| Subject | BALIPODECT | Small molecule | 30 mg | Oral |
| Subject | BALIPODECT | Small molecule | 300 mg | Oral |
| Background | Ketamine | Small molecule | — | Intravenous |